Your MTHFR Status Directly Affects Your Baby's Risk. Here's What You Need to Know.

MTHFR encodes the methylenetetrahydrofolate reductase enzyme, which converts folic acid into methylfolate, the active form your cells use for hundreds of reactions including DNA synthesis, neurotransmitter production, and myelin formation. Without this enzyme working efficiently, your cells can’t generate the building blocks needed for normal development.

The C677T variant, carried by roughly 35% of European populations and up to 50% in certain Asian populations, reduces MTHFR enzyme activity by 35-40%. The A1298C variant, present in about 30-50% of the population depending on ancestry, typically reduces activity by 20-30%. If you carry two copies of C677T, your enzyme works at only 30-40% of normal capacity. Even one copy of C677T significantly increases neural tube defect risk if folate status isn’t optimized. Compound heterozygotes (one C677T and one A1298C) face intermediate but still elevated risk.

During pregnancy, this matters intensely. Your baby’s neural tube closes around day 28 of gestation, often before you know you’re pregnant. If methylation capacity is low, neural tube closure can be incomplete, resulting in spina bifida or anencephaly. The risk isn’t absolute, but it’s measurably higher than the general population. Your folate needs during this critical window aren’t just higher in quantity; they require the specific form your compromised enzyme can actually process.

While MTHFR processes folate into its active form, the folate receptor protein (encoded by FOLR1) actually transports methylfolate across cell membranes and into the brain and spinal cord. During neural tube development, folate must reach the cells that are actively dividing and forming the spinal column and brain. If FOLR1 function is impaired, even adequate blood folate may not reach developing neural tissue.

Genetic variations in FOLR1 or downstream folate transport can reduce how efficiently folate gets into the cells that need it most during early pregnancy. Research suggests that folate transport capacity, separate from MTHFR enzyme activity, can independently increase neural tube defect risk. In some pregnancies with neural tube defects, folate blood levels are normal but cellular folate in neural tissue is depleted because transport is impaired.

This is why optimizing folate status requires more than just the right form. Your baby’s developing nervous system needs folate delivered efficiently into the exact cells building the neural tube. If either MTHFR or folate transport is compromised, the combination creates significant risk.

COMT breaks down stress-related neurotransmitters like dopamine and norepinephrine. During high stress or if you carry a slow-metabolizing COMT variant (such as Val158Met), these neurotransmitters accumulate, increasing cellular stress and methylation demand. Methylation is how your body neutralizes and clears excess catecholamines. The more stress your body experiences, the more methylation it consumes.

In pregnancy, stress is unavoidable and often intensifies anxiety about birth defects. If you also carry an MTHFR variant that reduces methylation capacity, plus a slow COMT variant that increases methylation demand, you have a double pinch: your cells need more methylation but can produce less. This combination can deplete methylation cofactors faster than standard prenatal supplementation replaces them. During the critical window of neural tube closure, this depletion matters.

Pregnancy itself is metabolically stressful. Your body is redirecting enormous resources to support your baby while managing hormonal changes and physical demands. If your COMT variant slows neurotransmitter clearance, stress accumulates, driving higher methylation demand precisely when your developing baby needs methylation resources most.

MTHFS catalyzes a step in folate recycling that converts formate back into the methylation cycle. This is critical for recovering folate molecules that would otherwise be lost, especially during periods of high metabolic demand like pregnancy. If MTHFS variants reduce enzyme efficiency, your body can’t recover and recycle folate as effectively, meaning you deplete folate stores faster.

Research in pregnancy cohorts suggests that MTHFS variants, often overlooked in standard prenatal screening, contribute to neural tube defect risk independently or in combination with MTHFR variants. Roughly 25-35% of the population carries variants that reduce MTHFS activity. During pregnancy, when folate demand increases 5-10 fold, reduced recycling efficiency becomes clinically meaningful.

If you have both reduced MTHFR efficiency and reduced MTHFS efficiency, your cells face a folate crisis during neural tube closure. You can’t convert folic acid efficiently and you can’t recycle the folate molecules you do process. Your folate pool becomes chronically inadequate despite normal blood levels.

MTR encodes methionine synthase, the enzyme that actually uses methylfolate to begin the methylation reactions your baby’s cells need. Without MTR function, methylfolate can accumulate in your cells without actually being used, a phenomenon called the methylfolate trap. MTR also depends on B12 as a critical cofactor. If MTR efficiency is reduced, B12 becomes even more essential.

MTR variants, particularly the A66G variant present in roughly 30-40% of the population, reduce methylation capacity by affecting how efficiently folate actually enters the methylation cycle. You can have high blood folate and normal MTHFR function but still have impaired methylation if MTR variants prevent that folate from being used. During neural tube development, when methylation demand is highest, this bottleneck can be the limiting factor.

Many women with MTR variants don’t improve with methylfolate alone because the problem isn’t converting folate but using it. They need B12 support and sometimes supplemental methylation donors like TMG or betaine to bypass the MTR bottleneck.

BHMT is your backup methylation pathway. When MTR can’t process folate fast enough, BHMT uses betaine (from choline and certain foods) to regenerate methionine and keep methylation moving. If BHMT variants reduce enzyme activity, your cells lose this critical backup system during periods of high demand. Pregnancy is a period of extraordinarily high demand.

BHMT variants, including common polymorphisms that reduce activity by 20-40%, are often overlooked because doctors focus on MTHFR and B12. But during pregnancy, especially if you also carry MTHFR or MTR variants, BHMT becomes essential for maintaining adequate methylation. If your primary methylation pathways are compromised and BHMT is also reduced, you have very limited capacity to meet your baby’s methylation needs during neural tube closure. Research on BHMT and neural tube defect risk is still emerging, but biochemically the link is clear.

Many women with multiple methylation-pathway variants don’t improve until BHMT is supported with adequate choline and betaine. This is why comprehensive methylation support looks at all the pathways, not just MTHFR.